Clinical Genomics, a Bridgewater-based development company, announced it has appointed Mark Boyle as president, In Vitro Diagnostics.
“Mark’s appointment comes at a critical time for our company,” Lawrence LaPointe, CEO and president of Clinical Genomics, said in a prepared statement. “As we planned for and recently announced the launch of Colvera, our two-gene test for CRC recurrence monitoring, we recognized the importance of placing a strong leader at the helm of our successful FIT-based screening franchise. With a career spanning more than two decades in the global IVD and life sciences markets, Mark brings a wealth of highly relevant experience that make him uniquely qualified to manage and grow our global FIT testing business.”
Boyle has 26 years of experience at various IVD and life sciences companies. Prior to Clinical Genomics, he was vice president at QIAGEN Inc. Previously, he was president of Cellestis Inc. He also was general manager for the U.K.-based subsidiary of Diagnostic Systems Laboratories Inc.